<DOC>
	<DOCNO>NCT01644240</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetics ( PK ) repeat IV dose TD-8954 healthy adult 18 45 year age healthy elderly subject 65 85 year old . A healthy elderly subject population include evaluate safety , tolerability , PK TD-8954 IV . Pharmacodynamic effect bowel movement also evaluate . Screening cohort conduct within 21 day first dose .</brief_summary>
	<brief_title>A Phase 1 , Multiple Intravenous Dose Study Examine Safety , Tolerability , Pharmacokinetics Intravenous TD-8954 , 5-HT4 Receptor Agonist , Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . For Cohorts 1 : adult male females age 18 45 year , inclusive ; Cohorts 2 3 , adult male females 65 85 year age , inclusive ; Cohort 4 , adult male females 18 45 65 85 year age , inclusive . 2 . Body mass index ( BMI ) 18 36 kg/m2 , inclusive . 3 . Average frequency â‰¥ 3 bowel movement per week . 1 . Persistent symptom functional GI disorder ( irritable bowel syndrome , functional constipation , functional dyspepsia , symptombased GI disorder unexplained pathologically base disorder ) 6 month prior screen , include history major surgery GI tract , exclude cholecystectomy appendectomy . 2 . History presence clinically significant respiratory , GI , renal , hepatic , endocrine , hematological , neurological ( include chronic headache , current prior psychiatric disease/condition , stroke ) , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological disorder . Subjects mild , chronic , stable disease ( e.g. , control hypertension , control hypercholesterolemia , non insulindependent diabetes , osteoarthritis ) may enrol condition well control anticipate interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>